Wells Fargo & Company Cyteir Therapeutics, Inc. Transaction History

Wells Fargo & Company

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$2.84 - $3.13 $22 - $25	8 Added 5.76%	147 $0
Q3 2023 Nov 13, 2023	BUY	$2.71 - $2.84 $100 - $105	37 Added 36.27%	139 $0
Q2 2023 Aug 15, 2023	BUY	$1.74 - $2.6 $6 - $10	4 Added 4.08%	102 $0
Q1 2023 May 12, 2023	BUY	$1.47 - $1.84 $1 - $1	1 Added 1.03%	98 $0
Q4 2022 Feb 13, 2023	BUY	$1.18 - $1.76 $3 - $5	3 Added 3.19%	97 $0
Q3 2022 Nov 14, 2022	BUY	$1.99 - $4.05 $87 - $178	44 Added 88.0%	94 $0
Q2 2022 Aug 12, 2022	SELL	$1.62 - $4.4 $5,687 - $15,448	-3,511 Reduced 98.6%	50 $0
Q1 2022 May 16, 2022	SELL	$3.39 - $10.51 $2,966 - $9,196	-875 Reduced 19.72%	3,561 $13,000
Q4 2021 Feb 14, 2022	BUY	$9.83 - $19.21 $43,183 - $84,389	4,393 Added 10216.28%	4,436 $50,000
Q3 2021 Nov 15, 2021	BUY	$14.57 - $21.86 $626 - $939	43 New	43 $1,000

2.47M

Ticker CYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,413,400
Market Cap $107M
Description
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for c...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.